07.20.18
Headquarters: Lexington, MA
twitter.com/shireplc
www.shire.com
Headcount: 22,000
Year Established: 1986
Revenues: $14,449 (+33%)
Net Income: $4,272 (n/a)
R&D: $1,763 (+23%)
Top Selling Drugs
Shire made major headlines this year surrounding the anticipated sale of the company. After rejecting numerous bids and offers, Japanese rival Takeda, finally came to an agreement to buy Shire for a whopping $62 billion. It represents one of the biggest pharma deals in history, and the largest-ever international takeover by any Japanese company. The deal is expected to close in the first half of 2019, and it wasn’t Shire’s only major sale of the year. In addition, Shire also announced the sale of its Oncology business to Servier S.A.S. for $2.4 billion. Shire’s Oncology business, which brought in $292 million in revenue in 2017, includes in-market products Oncaspar, Onivyde, and Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of acute lymphoblastic leukemia, as well as an early stage immuno-oncology pipeline. Shire says that while the business has delivered high growth and profitability, the company concluded that it is not core to Shire’s longer-term strategy.
This year also brought numerous approvals for Shire. In June 2017, The FDA approved Mydayistm, a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with ADHD. The FDA also approved a label expansion for Cinryze, making it available to help prevent angioedema attacks in children aged 6 years and older with hereditary angioedema. The condition results in recurring swelling in various parts of the body, including the abdomen, face, feet, hands and throat that can be can debilitating and painful.
Collaborations during the year were plentiful for Shire as well, especially within the area of Hemophilia. Notably, Novimmune S.A. entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in preclinical development for the treatment of hemophilia A and hemophilia A patients with inhibitors.
Shire also entered into a collaboration with MicroHealth to support a free and secure care monitoring tool for hemophilia A and B patients with inhibitors. MicroHealth developed the app to help improve hemophilia patient care and outcomes through the ability to set reminders, track, store and selectively share personal health data with care team members. Shire’s role in the partnership is to help the start-up customize the tool with new features and information specifically for the 5-7 percent of hemophilia patients with inhibitors.
twitter.com/shireplc
www.shire.com
Headcount: 22,000
Year Established: 1986
Revenues: $14,449 (+33%)
Net Income: $4,272 (n/a)
R&D: $1,763 (+23%)
Top Selling Drugs
Drug | Indication | 2017 Sales | (+/-%) |
Hemophilia | hematology | $2,957 | 65% |
Immunoglobulin Therapies | immunology | $2,237 | 96% |
Vyvanse | ADHD | $2,161 | 7% |
Cinryze | hereditary angioedema | $699 | 3% |
Elaprase | Hunter syndrome | $616 | 5% |
Lialda | ulcerative colitis | $570 | -28% |
Shire made major headlines this year surrounding the anticipated sale of the company. After rejecting numerous bids and offers, Japanese rival Takeda, finally came to an agreement to buy Shire for a whopping $62 billion. It represents one of the biggest pharma deals in history, and the largest-ever international takeover by any Japanese company. The deal is expected to close in the first half of 2019, and it wasn’t Shire’s only major sale of the year. In addition, Shire also announced the sale of its Oncology business to Servier S.A.S. for $2.4 billion. Shire’s Oncology business, which brought in $292 million in revenue in 2017, includes in-market products Oncaspar, Onivyde, and Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of acute lymphoblastic leukemia, as well as an early stage immuno-oncology pipeline. Shire says that while the business has delivered high growth and profitability, the company concluded that it is not core to Shire’s longer-term strategy.
This year also brought numerous approvals for Shire. In June 2017, The FDA approved Mydayistm, a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with ADHD. The FDA also approved a label expansion for Cinryze, making it available to help prevent angioedema attacks in children aged 6 years and older with hereditary angioedema. The condition results in recurring swelling in various parts of the body, including the abdomen, face, feet, hands and throat that can be can debilitating and painful.
Collaborations during the year were plentiful for Shire as well, especially within the area of Hemophilia. Notably, Novimmune S.A. entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in preclinical development for the treatment of hemophilia A and hemophilia A patients with inhibitors.
Shire also entered into a collaboration with MicroHealth to support a free and secure care monitoring tool for hemophilia A and B patients with inhibitors. MicroHealth developed the app to help improve hemophilia patient care and outcomes through the ability to set reminders, track, store and selectively share personal health data with care team members. Shire’s role in the partnership is to help the start-up customize the tool with new features and information specifically for the 5-7 percent of hemophilia patients with inhibitors.